Evidence map›Paper›PMID 35654482›Full record

ArticleLupus science & medicine2022

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis.

Takehiro Nakai, Sho Fukui, Yukihiko Ikeda, Masei Suda, Hiromichi Tamaki, Masato Okada

Open access · goldAbstract read
In one paragraph

Article in Lupus science & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Takehiro NakaiImmuno-Rheumatology Center, St Luke's International Hospital, Chuo-ku, Japan nowhereman1106@outlook.jp.ORCID 0000-0003-0588-9518
Sho FukuiImmuno-Rheumatology Center, St Luke's International Hospital, Chuo-ku, Japan.ORCID 0000-0002-3082-1374
Yukihiko IkedaImmuno-Rheumatology Center, St Luke's International Hospital, Chuo-ku, Japan.
Masei SudaImmuno-Rheumatology Center, St Luke's International Hospital, Chuo-ku, Japan.
Hiromichi TamakiImmuno-Rheumatology Center, St Luke's International Hospital, Chuo-ku, Japan.
Masato OkadaImmuno-Rheumatology Center, St Luke's International Hospital, Chuo-ku, Japan.
St. Luke's International Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLong-term glucocorticoid use in SLE may have significant side effects; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the risk factors for disease flares and the flare rate on glucocorticoid tapering in patients with prior severe organ involvement.

methodsData of patients with SLE with glucocorticoid tapering at our institution were retrospectively analysed. We divided the patients by the presence of prior severe organ involvement and compared flare rates after glucocorticoid discontinuation. Furthermore, we determined risk factors for flares after glucocorticoid discontinuation.

resultsIn total, 309 patients with SLE were screened, 73 of whom met the inclusion criteria; 49 were classified as SLE with prior severe organ involvement. No significant differences were noted in the 52-week flare rate after glucocorticoid discontinuation between patients with and without prior severe organ involvement (16.7% vs 18.2%, p=1.0). Hypocomplementaemia, elevated anti-dsDNA antibody titres more than twice the upper limit of the laboratory reference range, positive anti-Smith/anti-ribonucleoprotein antibody, and use of any immunosuppressant on the day of glucocorticoid discontinuation were negatively associated with flare-free remission.

conclusionsGlucocorticoid discontinuation after gradual tapering can often be achieved in patients with SLE, even with prior severe organ involvement, especially when the disease is clinically and serologically stable.

Indexed as

GlucocorticoidsLupus Erythematosus, SystemicAntibodies, AntinuclearHumansRetrospective StudiesAntibodies, Antinuclearanti-dsDNA autoantibodyGlucocorticoidsGlucocorticoidsLupus Erythematosus, SystemicTherapeutics

Identifiers

PMID35654482
PMCPMC9163542
OpenAlexW4281742192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.